GSK plc

GSK plc OCF/Debt

The Operating Cash Flow to Debt Ratio of GSK plc (GSK.L) as of Nov 12, 2026 is 41.21 %. In the previous year, Operating Cash Flow to Debt Ratio was 38.58 % — a change of 6.81% (higher).

OCF/Debt

41.21 %

YoY

6.81%

Last updated:

Operating Cash Flow to Debt Ratio of GSK plc is 2025 41.21 % . Operating Cash Flow to Debt Ratio of GSK plc was 2024 38.58 % . It decreases by 6.81% higher compared to the previous year.

The GSK plc OCF/Debt history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

OCF/Debt
Date
OCF/Debt
Jan 1, 2018
32.31 GBP
Jan 1, 2019
26.29 GBP
Jan 1, 2020
31.09 GBP
Jan 1, 2021
32.90 GBP
Jan 1, 2022
35.27 GBP
Jan 1, 2023
37.56 GBP
Jan 1, 2024
38.58 GBP
Jan 1, 2025
41.21 GBP
The GSK plc OCF/Debt history
YEAROCF/DebtYoY
41.21 %+6.81%
38.58 %+2.72%
37.56 %+6.49%
35.27 %+7.23%
32.90 %+5.81%
31.09 %+18.27%
26.29 %-18.63%
32.31 %-20.19%
40.48 %+17.08%
34.58 %+123.85%
15.45 %-43.95%
27.56 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

GSK plc Stock analysis

What does GSK plc do? GSK plc generates revenue through its Pharmaceuticals and Vaccines segments, which focus on developing and selling prescription medicines and vaccines. The Pharmaceuticals segment offers products in Respiratory, HIV, Specialty, and Classic and Established categories, targeting acute and chronic diseases. The Vaccines segment provides over 40 vaccines for pediatric, adolescent, adult, and older populations, including travel vaccines. Customers include healthcare providers, hospitals, and consumers purchasing over-the-counter products. GSK's brand portfolio spans prescription medicines like those for Respiratory and HIV, alongside vaccines such as those for pediatric and adult health. The company's research focuses on six therapeutic areas: Respiratory diseases, HIV/infectious diseases, Vaccines, Immuno-inflammation, Oncology, and Rare diseases. This research drives product development for both segments, ensuring a steady pipeline of medicines and vaccines. The company's products are distributed globally, with the Pharmaceuticals business targeting healthcare professionals and the Vaccines business serving public health programs and individual consumers. GSK's strategy emphasizes innovation in key therapeutic areas to address unmet medical needs, leveraging its extensive research and development capabilities to maintain market leadership. GSK plc is one of the most popular companies on Eulerpool.

Frequently Asked Questions about GSK plc stock

Operating Cash Flow to Debt Ratio of GSK plc is 41.21 % in 2025.

Operating Cash Flow to Debt Ratio of GSK plc changed from 38.58 % to 41.21 %, representing a 6.81% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Operating Cash Flow to Debt Ratio GSK plc since 2006 – with annual values, charts, and detailed analysis.

OCF/Debt measures what percentage of total debt can be covered by annual operating cash flow. Higher ratios indicate stronger debt repayment capacity.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Operating Cash Flow to Debt Ratio's GSK plc with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — GSK plc

All Key Metrics — GSK plc